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Abstract: Human influenza A(H2N2) viruses emerged in 1957 and were replaced by A(H3N2) viruses
in 1968. The antigenicity of human H2N2 viruses has been tested by using ferret antisera or mouse
and human monoclonal antibodies. Here, we examined the antigenicity of human H2N2 viruses
by using human plasma samples obtained from 50 aged individuals who were born between 1928
and 1933 and from 33 younger adult individuals who were born after 1962. The aged individuals
possessed higher neutralization titers against H2N2 viruses isolated in 1957 and 1963 than those
against H2N2 viruses isolated in 1968, whereas the younger adults who were born between 1962 and
1968 possessed higher neutralization titers against H2N2 viruses isolated in 1963 than those against
other H2N2 viruses. Antigenic cartography revealed the antigenic changes that occurred in human
H2N2 viruses during circulation in humans for 11 years, as detected by ferret antisera. These results
show that even though aged individuals were likely exposed to more recent H2N2 viruses that are
antigenically distinct from the earlier H2N2 viruses, they did not possess high neutralizing antibody
titers to the more recent viruses, suggesting immunological imprinting of these individuals with the
first H2N2 viruses they encountered and that this immunological imprinting lasts for over 50 years.
Keywords: influenza A virus; aged individuals; H2N2; antigenic drift; antigenic change
1. Introduction
In 1957, an influenza A(H2N2) virus caused the so-called Asian flu. The pandemic H2N2 virus
became a seasonal influenza virus and continued to circulate until 1968, when the H3N2 pandemic
virus replaced the H2N2 virus [1]. The H2N2 viruses have not circulated in the human population
since then. Therefore, most humans who were born after 1968 lack immunity, including neutralizing
antibodies, to the H2N2 viruses [2,3].
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Between 1957 and 1968, the human H2N2 viruses accumulated amino acid mutations in their
HAs to escape from neutralizing antibodies [4] and adapt to humans [5], which may have altered their
antigenicity. In fact, ferret antisera against several H2N2 isolates were used to reveal differences in
antigenicity among the human H2N2 isolates [6–8]. Mouse or human monoclonal antibodies were
also used to characterize antigenic changes in the HA [9,10]; however, these experiments used H2N2
isolates that were propagated in embryonated chicken eggs with egg-adapted amino acid mutations in
the HA that affect the HA antigenicity. To solve this problem, Linster et al. [11] collected H2N2 isolates
that were obtained by culture in tertiary monkey kidney cells and/or MDCK cells for a maximum of
five passages, without prior inoculation into embryonated chicken eggs. Using such isolates and ferret
antisera against these isolates, they found antigenic changes among H2N2 viruses isolated between
1957 and 1968 [11]. The T128D and N139K substitutions together with the E126T, S154P, A184T, and
A188T substitutions around the receptor-binding site of HA were important for the antigenic changes
in the H2N2 viruses [11].
In this study, we performed a serological examination of human plasma samples obtained from
50 aged individuals who were born between 1928 and 1933 and 33 younger adult individuals who
were born after 1962 to examine how the human immune system sees antigenic changes in human
H2N2 viruses.
2. Materials and Methods
2.1. Ethical Issues
All protocols and experiments in this study were approved by the ethics committees of the
Institute of Medical Science at the University of Tokyo (ID: 26-65-1119; date: 7 April 2018) and the
Keio University School of Medicine (ID: 20160297; date: 2 April 2018. Written informed consent
was obtained from all participants in this study. The Kawasaki Wellbeing Project is registered in the
University Hospital Medical Information Network Clinical Trial Registry (ID: UMIN000026053).
2.2. Sample Collection
Plasma samples were collected from 50 aged individuals who were born between 1928 and 1933
(85–89 years old) (Table 1). These individuals had participated in the Kawasaki Wellbeing Project,
which recruits healthy individuals aged 85–89 years-old, from May to July 2018. Plasma samples from
33 younger adult volunteers born after 1962 (23–55 years old), who participated in a seasonal influenza
vaccine surveillance project, were collected before these individuals received the seasonal influenza
vaccine from January to November 2018 (Table 1). Information on the vaccination history of most
of the individuals was limited. Each blood sample was collected in a 5-mL vacuum tube containing
EDTA-2Na (Terumo, Tokyo, Japan). Plasma was separated from whole blood by using a Leucosep
(Greiner Bio-One, Kremsmünster, Austria) and was stored at −20 ◦C until use.
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Table 1. Characteristics of the participants in this study.
No. of Individuals
Birth Year
Aged Individuals Younger Adult Individuals
1928 1929 1930 1931 1932 1933 1960s 1970s 1980s 1990s
Males 4 4 4 4 4 4 10 5 1 2
Females 5 5 4 4 4 4 9 3 2 1
Total 9 9 8 8 8 8 19 8 3 3
Medical
history b
Heart disease 3/9 1/9 3/8 1/8 1/8 1/8 NA a NA NA NA
Diabetes 0/9 0/9 1/8 2/8 1/8 1/8 NA NA NA NA
Cancer 3/9 2/9 2/8 4/8 2/8 2/8 NA NA NA NA
a Not available. b Summary of available medical history of each individual.
2.3. Biosafety Consideration
All experiments with human H2N2 viruses were conducted in a biosafety level (BSL) 3 laboratory
at the University of Tokyo, which is approved for such use by the Ministry of Agriculture, Forestry,
and Fisheries, Japan.
2.4. Cells and Viruses
Madin–Darby canine kidney (MDCK) cells were maintained in Eagle’s minimal essential
medium (MEM) containing 5% newborn calf serum at 37 ◦C in 5% CO2. Influenza A(H2N2)
viruses, A/Netherlands/M1/57 (M1/57), A/Netherlands/K1/63 (K1/63), A/Netherlands/B1/68 (B1/68),
and A/Netherlands/B2/68 (B2/68), were kindly provided by Ron Fouchier (Eramus Medical Center,
Rotterdam, Netherlands) [11]. The isolates were obtained by culture in tertiary monkey kidney cells
and/or MDCK cells for a maximum of five passages, without prior inoculation into embryonated
chicken eggs [11]. The 50% tissue culture infectious dose (TCID50) was determined with MDCK cells
and the Reed and Muench formula.
2.5. Virus Neutralization Assay
Virus neutralization assays were conducted by using the methodology described in the WHO
manual on Animal Influenza Diagnosis and Surveillance (http://www.wpro.who.int/emerging_diseases/
documents/docs/manualonanimalaidiagnosisandsurveillance.pdf) with some modifications. Briefly,
plasma samples were initially treated with a receptor-destroying enzyme (RDE II, DENKA SEIKEN Co.,
LTD, Tokyo, Japan) to remove non-specific inhibitors. Two-fold serially diluted plasma samples were
mixed with 100 TCID50 of each isolate. The mixtures were incubated for 30 min at 37 ◦C and were then
inoculated into an MDCK monolayer in a 96-well microplate. Cytopathic effect was observed to detect
the presence of viral propagation 3 days after inoculation. The reciprocal number of the minimum
dilution of plasma needed to suppress the appearance of CPE was used as the neutralization titer.
2.6. Phylogenetic Analysis
The HA sequences of 17 viruses described previously [11] were aligned using the software
of ClustalW. The phylogenetic tree was inferred by using the Maximum Likelihood method and
Jones-Taylor-Thornton (JTT) matrix-based model [12]. The tree with the highest log likelihood
(−1787.57) is shown. The percentage of trees in which the associated taxa clustered together is shown
next to the branches. Initial tree(s) for the heuristic search were obtained automatically by applying
Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using a JTT model,
and then selecting the topology with the superior log likelihood value. The tree is drawn to scale,
with branch lengths measured in the number of substitutions per site. There were 329 positions
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in the final dataset. Evolutionary analyses were conducted by using the software MEGA X [4].
A/mallard/Netherlands/31/2006 virus is defined as an outgroup.
2.7. Statistical Analysis
A non-parametric, repeated measures, one-way ANOVA Friedman’s test followed by a two-stage
linear step-up procedure of Benjamini, Krieger, and Yekutieli was performed by using GraphPad Prism
7.04 software. p values <0.05 were considered significantly different. No samples were excluded from
the analysis.
2.8. Antigenic Cartography
The neutralization data were analyzed by using antigenic cartography (https://acmacs-web.
antigenic-cartography.org/), which is a method to visualize and increase the resolution of neutralization
results, as detailed previously [13]. Plasma samples with no or only one numerical antibody titer were
not included because they cannot be placed properly in an antigenic map.
3. Results and Discussions
To examine the antigenicity of the H2N2 viruses that circulated in humans, we used 50 plasma
samples that were obtained from aged individuals (Table 2) because individuals who were born
between 1928 and 1933 were likely exposed to human H2N2 viruses between 1957 and 1968. We
also used 33 plasma samples from younger adults who were born after 1962 (Table 2). We chose 4
human H2N2 isolates—A/Netherlands/M1/57 (H2N2; M1/57), A/Netherlands/K1/63 (H2N2; K1/63),
A/Netherlands/B1/68 (H2N2; B1/68), and A/Netherlands/B2/68 (H2N2; B2/68)—based on phylogenic
analysis (Figure 1) and a previous report [11]. These isolates were obtained by culture in tertiary
monkey kidney cells and MDCK cells for a maximum of five passages, without prior inoculation into
embryonated chicken eggs [11].
Viruses 2019, 11, 978 4 of 9 
 
3. Results and Discussions 
To examine the antigenicity of the H2N2 viruses that circulated in humans, we used 50 plasma 
samples that were obtained from aged individuals (Table 2) because individuals who were born 
between 1928 and 1933 were likely exposed to human H2N2 viruses between 1957 and 1968. We also 
used 33 plasma samples from younger adults who were born after 1962 (Table 2). We chose 4 human 
H2N2 isolates—A/Netherlands/M1/57 (H2N2; M1/57), A/Netherlands/K1/63 (H2N2; K1/63), 
A/Netherlands/B1/68 (H2N2; B1/68), and A/Netherlands/B2/68 (H2N2; B2/68)—based on phylogenic 
analysis (Figure 1) and a previous report [11]. These isolates were obtained by culture in tertiary 
onkey kidney cells and MDCK cells for a maximum of five passages, without prior inoculation into 
embryonated chicken eggs [11]. 
 
Figure 1. Phylogenetic tree based on the amino acid sequences of HA1 derived from human H2N2 
viruses. This tree was constructed by using the Maximum Likelihood method and JTT matrix-based 
model. Virus isolates used for antigenic analysis are highlighted in magenta. 
Table 2. Neutralization titers of aged and younger adult individuals. 
ID Birth Year (age) M1/57 a K1/63 b B1/68 c B2/68 d 
1 1928 (89) 128 8 8 8 
2 1928 (89) 8 32 4 16 
3 1928 (89) 64 32 <4 16 
4 1928 (89) 32 32 4 8 
5 1928 (89) 256 128 32 8 
6 1928 (89) 64 32 <4 16 
7 1928 (89) 256 32 16 16 
8 1928 (89) 128 64 4 32 
9 1928 (89) 8 16 <4 <4 
10 1929 (89) 64 32 8 16 
11 1929 (89) 8 32 <4 <4 
12 1929 (89) 128 64 4 8 
13 1929 (89) 8 32 <4 8 
14 1929 (89) 256 64 4 4 
15 1929 (89) 32 8 <4 4 
16 1929 (89) 32 32 4 <4 
17 1929 (88) 32 64 8 8 
18 1929 (88) 32 128 4 16 
19 1930 (88) 16 16 <4 8 
20 1930 (88) 16 8 4 4 
21 1930 (88) 32 64 <4 8 
22 1930 (88) 256 64 8 4 
Figure 1. Phylogenetic tre based on the amino acid sequences of HA1 derived from human H2N2
viruses. This tre was constructed by using the Maximum Likeliho d method and JT matrix-based
model. Virus isolates used for antigenic analysis are highlighted in magenta.
Viruses 2019, 11, 978 5 of 10
Table 2. Neutralization titers of aged and younger adult individuals.
ID Birth Year (age) M1/57 a K1/63 b B1/68 c B2/68 d
1 1928 (89) 128 8 8 8
2 1928 (89) 8 32 4 16
3 1928 (89) 64 32 <4 16
4 1928 (89) 32 32 4 8
5 1928 (89) 256 128 32 8
6 1928 (89) 64 32 <4 16
7 1928 (89) 256 32 16 16
8 1928 (89) 128 64 4 32
9 1928 (89) 8 16 <4 <4
10 1929 (89) 64 32 8 16
11 1929 (89) 8 32 <4 <4
12 1929 (89) 128 64 4 8
13 1929 (89) 8 32 <4 8
14 1929 (89) 256 64 4 4
15 1929 (89) 32 8 <4 4
16 1929 (89) 32 32 4 <4
17 1929 (88) 32 64 8 8
18 1929 (88) 32 128 4 16
19 1930 (88) 16 16 <4 8
20 1930 (88) 16 8 4 4
21 1930 (88) 32 64 <4 8
22 1930 (88) 256 64 8 4
23 1930 (87) 64 64 4 16
24 1930 (87) 128 32 4 32
25 1930 (87) 256 16 4 16
26 1930 (87) 256 64 8 8
27 1931 (87) 128 64 4 32
28 1931 (87) 16 16 <4 <4
29 1931 (87) 16 64 8 16
30 1931 (87) 32 16 4 16
31 1931 (86) 32 16 <4 <4
32 1931 (86) 32 4 <4 4
33 1931 (86) 32 32 <4 4
34 1931 (86) 128 32 4 8
35 1932 (86) 256 32 8 4
36 1932 (86) 32 32 <4 32
37 1932 (86) 256 32 8 4
38 1932 (86) 16 8 <4 8
39 1932 (86) 256 128 <4 8
40 1932 (85) 256 32 8 16
41 1932 (85) 32 32 <4 4
42 1932 (85) 64 64 4 4
43 1933 (85) 16 16 8 16
44 1933 (85) 256 64 8 8
45 1933 (85) 256 32 4 <4
46 1933 (85) 32 16 4 4
47 1933 (85) 128 64 8 16
48 1933 (85) >512 128 64 64
49 1933 (85) 64 64 8 16
50 1933 (85) 8 128 4 4
51 1962 (56) 4 64 8 128
52 1962 (55) <4 16 4 4
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Table 2. Cont.
ID Birth Year (age) M1/57 a K1/63 b B1/68 c B2/68 d
53 1962 (55) 8 32 16 32
54 1962 (55) 16 32 8 8
55 1963 (55) 32 >512 32 64
56 1963 (55) 32 >512 64 256
57 1963 (55) 8 128 64 64
58 1963 (55) 16 256 16 32
59 1964 (54) 8 128 8 32
60 1965 (53) 4 64 4 32
61 1966 (52) 8 32 8 32
62 1966 (51) 8 128 16 64
63 1967 (51) 4 64 16 16
64 1967 (50) <4 32 4 8
65 1968 (50) <4 4 <4 <4
66 1968 (49) 4 16 4 8
67 1969 (49) 4 32 8 32
68 1969 (49) <4 <4 <4 <4
69 1969 (48) 4 16 4 16
70 1970 (48) 8 4 8 16
71 1970 (47) <4 8 4 32
72 1970 (47) <4 8 <4 16
73 1970 (47) <4 16 8 4
74 1970 (47) <4 4 <4 8
75 1972 (45) <4 <4 <4 <4
76 1974 (44) <4 <4 <4 4
77 1978 (39) <4 <4 <4 <4
78 1980 (37) <4 <4 <4 <4
79 1982 (36) <4 <4 <4 <4
80 1985 (33) <4 <4 <4 <4
81 1990 (27) <4 <4 <4 <4
82 1992 (26) <4 <4 <4 4
83 1994 (23) <4 <4 <4 4
Neutralization titers of plasma samples of aged individuals (ID 1–50) and younger adult individuals (ID 51–83)
against A/Netherland/M1/57 a, A/Netherland/K1/63 b, A/Netherland/B1/68 c, or A/Netherland/B2/68 d were measured.
Using these 83 plasma samples and four human H2N2 isolates, we performed a virus neutralization
assay to compare the antigenicity of the human H2N2 isolates (Table 2). The aged individuals (ID
#1–50) possessed higher neutralization titers against M1/57 and K1/63 than those against B1/68 and
B2/68 (Figure 2A,C). The neutralizing titers against B1/68 of the aged individuals were lower than
those against B2/68, whereas those against M1/57 were similar to those against K1/63 (Figure 2A,C).
The neutralizing titers against K1/63 and B2/68 of the younger adult individuals were higher than
those against M1/57 and B1/68 (Figure 2B,C). Younger adults who were born after 1972 (ID #75–83)
had minimal neutralization titers against the human H2N2 viruses tested (Figure 2C). To visualize
the antigenicity of the human H2N2 viruses, we constructed an antigenic map using the neutralizing
titers of Table 2. This map revealed the antigenic differences among the H2N2 viruses tested and the
gradual drift in their antigenicity during circulation in humans (Figure 3). The results obtained with
these human sera were similar to those previously obtained using ferret antisera [11].
Viruses 2019, 11, 978 7 of 10Viruses 2019, 11, 978 7 of 9 
 
 
Figure 2. Neutralization titers of aged individuals (A) and younger adult individuals (B) against 
human H2N2 viruses. The neutralization titers against the viruses indicated in Table 2 were plotted. 
A non-parametric Friedman’s test followed by a two-stage linear step-up procedure of Benjamini, 
Krieger, and Yekutieli was performed. * and *** mean p < 0.05 and p < 0.0001, respectively. (C) Bubble 
chart of the neutralization titers of all of the individuals. The bigger the circle, the higher the 
neutralization titer. 
Table 3. Comparison of amino acids that are important for HA antigenicitya. 
Isolate 
Amino acid position at 
126 128 132 139 154 184 188 
A/Netherland/M1/57 T T R N S T T 
A/Netherland/K1/63 T T R N P A A 
A/Netherland/B1/68 E D K K P A A 
A/Netherland/B2/68 K D K K Q E A 
aAmino acids that are different among the HAs of the four isolates at previously identified antigenic 
determinants [11] are listed.  
Figure 2. Neutralization titers of aged individuals (A) and younger adult individuals (B) against
human H2N2 viruses. The neutralization titers against the viruses indicated in Table 2 were plotted.
A non-parametric Friedman’s test followed by a two-stage linear step-up procedure of Benjamini,
Krieger, and Yekutieli was performed. * and *** mean p < 0.05 and p < 0.0001, respectively. (C) Bubble
chart of the neutralization titers of all of the individuals. The bigger the circle, the higher the
neutralization titer.
Human H2N2 viruses circulated in the human population between 1957 and 1968. Mouse and
human monoclonal antibodies [9,10] and ferret antisera [6–8,11] revealed the antigenic change in
H2N2 viruses. Here, we elucidated the antigenic change i H2N2 viruses by using 83 human plasma
samples that were obtained from the aged and younger adult individuals. Overall, the antigenicity
of H2N2 viruses revealed by human plasma was similar to that revealed by ferret antisera. Ferret
antisera showed that the antigenic change between M1/57 and B1/68 was caused by the T128D and
R139K substitutions together with other five other changes (Table 3). These substitutions may play
a central role in the antigenic change revealed by human plasma since some human neutralizing
monoclonal antibodies against H2-HA recognize the region surrounding these seven amino acids [10].
Furthermore, human plasma showed that the antigenicity of B1/68 differed from that of B2/68. At the
seven amino acid positions that were important for the antigenic change between M1/57 and B1/68,
E126K, P154Q, and A184E substitutions are present between B1/68 and B2/68 (Table 3). These 3 amino
acid substitutions may, therefore, contribute to the antigenic difference between the viruses.
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Although some of the aged individuals likely have been infected with or exposed to later H2N2
viruses, almost of all of the aged individuals maintained high neutralization titers against the H2N2
viruses that caused the pandemic or its antigenically closely related viruses, but possessed low
neutralization titers against later H2N2 viruses. These data suggest that immunological imprinting
toward the pandemic H2N2 virus occurred. This would also mean that t e immu ological imprinting
was maintained for 50 years.
Antigenic cartography is usually rformed by using antisera obtained from ferr ts infected
with an influenza virus [13]. In this study, we u ed human plasm samples obtained from aged nd
younger adults for the ntigenic cartography of human H2N2 viruses. Previous studies showed that
human infant sera and ferret antisera see the antigenicity of H1N1 and H3N2 viruses differently [14,15].
However, the positions of four H2N2 viruses in the antigenic map we made with the human plasma
samples were similar to those obtained with ferret antisera (Figure 3 and ref [11]). This variation in
findings with respect to the antigenic differences recognized by human sera/plasma and ferret antisera
between H2N2 and H1N1 or H3N2 is interesting and deserves further study.
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Human H2N2 viruses were replaced by human H3N2 viruses in 1968. Therefore, we had thought
that people who were born after 1968 were unlikely to possess neutralizing antibodies against human
H2N2 viruses. However, they did possess some neutralization titers against the H2N2 viruses. This
finding could be explained by antibodies against the HA stem and/or NA because anti-HA stem
antibodies are usually cross-reactive with members of group 1 HA [16–18] and antibodies against the
NA of the seasonal H3N2 virus could suppress H2N2 virus replication, given that the NA of H3N2
virus was inherited from human H2N2 virus [1].
In conclusion, the plasma of individuals who were born between 1928 and 1933 revealed the
antigenic change in human H2N2 viruses and the possibility of immunological imprinting of infected
individuals against pandemic H2N2 virus, which lasts for half a century.
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